We are committed to improving the lives of patients

Kadmon offers a portfolio of products for the treatment of serious and rare diseases.

Capecitabine Tablets, USP capecitabine tablets, USP

Temozolomide Capsules temozolomide capsules

Tobramycin Inhalation Solution, USP tobramycin Inhalation solution, USP

Tetrabenazine tetrabenazine tablets

Valganciclovir valganciclovir tablets, USP

Lamivudine lamivudine tablets (HBV)

Lamivudine and Zidovudine lamivudine and zidovudine tablets, USP

Medical Information
For product inquiries or to report an adverse event or product quality complaint for a Kadmon marketed product, please call 1.877.377.7862. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1.800.FDA.1088.

Consumer Product Safety Improvement Act (CPSIA) Certification
In accordance with the CPSIA of 2008, Kadmon certifies that our product’s child-resistant packaging comply with the standards established under the Poison Prevention Packaging Act of 1970 as amended. To receive a copy of a CPSIA certificate for a Kadmon product, please contact Medical Information at 1.877.377.7862 or